Overexpression of PD-L1 in cancer cells correlates with drug resistance and poor prognosis.82–90 Therefore, anti-PD-1 immunotherapy has gained enormous clinical relevance and its suitability in different conditions is the focus of hundreds of clinical trials (https://clinicaltrials.gov/). Here, PDCD1 is linked to cancer.